News

Dana-Farber/Boston Children’s faculty named 2020 Top Doctors

Boston magazine has named at least 25 faculty members of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center to its annual "Top Doctors" guide.

Dana-Farber/Boston Children’s Hojun Li named a 2020 Scholar Award Recipient by the American Society of Hematology

One of ASH’s most prestigious research award programs, the ASH Scholar Awards financially support fellows to junior faculty dedicated to careers in hematology research as they transition from training programs to careers as independent investigators.

Dana-Farber/Boston Children's launches first DIPG Brain Tumor Consortium

Earlier this month, diffuse intrinsic pontine glioma (DIPG) researchers from several pediatric hospitals around the country gathered in Boston to share their innovative ideas.

Stuart Orkin and Daniel Bauer receive funding for sickle cell disease research from the Doris Duke Charitable Foundation

The Doris Duke Charitable Foundation announced the six projects receiving approximately $5 million through the second Sickle Cell Disease/Advancing Cures grant competition.

“Stapled” antimicrobial peptides could combat antibiotic resistance

The peptides, folded into specific three-dimensional shapes using chemical “staples” for reinforcement, kill multidrug resistant bacteria but don’t harm red blood cells or other normal tissues.

Leonard Zon, MD, honored by the American Society of Hematology for Outstanding Mentorship

The ASH Mentor Award recognizes hematologists who have excelled in mentoring trainees and colleagues.

Dana-Farber/Boston Children's nation’s #1 pediatric cancer program

U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the nation’s #1 pediatric cancer program in its new 2019-20 Best Children’s Hospitals rankings.

Katherine E. Warren, MD, joins Dana-Farber/Boston Children’s as Clinical Director for Pediatric Neuro-Oncology

Warren is an internationally recognized expert in pediatric neuro-oncology. Her work focuses on rational, pharmacokinetic-based drug development for children with brain tumors, and she is a leading innovator in developing new means of drug delivery.

Lynda M. Vrooman to present findings from Dana-Farber/Boston Children’s clinical trial that led to FDA approval of novel drug for treatment of ALL in young patients

Vrooman will share the abstract at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Children with cancer wait an average of 6.5 years longer than adults to access new targeted drugs, finds study at Dana-Farber/Boston Children’s

Researchers call for expanding children’s access to experimental cancer therapies